This activity is expired and is no longer available for CME credit.


Hot Topics in RA: Debates and Discussion from Rome

Author(s)/Faculty: Eric M. Ruderman, MD; Leonard H. Calabrese, DO; Stanley B. Cohen, , MD; Jeffrey Curtis, MD, MS, MPH
Release Date: 10/13/2015Expiration Date: 9/10/2019
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Methotrexate (MTX) has served as the cornerstone of rheumatoid arthritis (RA) therapy for decades. However, with new and emerging biologic and small molecule disease modifying antirheumatic drugs (DMARDs) entering the therapeutic scene, more options are now available for patients refusing to take MTX or those experiencing MTX intolerance or inadequate response. In this expert panel, recent data comparing mono- and combination therapy will re-evaluate the role of the various DMARDs in the initiation and maintenance of RA treatment, explore emerging methods of personalizing therapy, and delve into therapeutic options after initial biologic DMARD failure.